HYPERPROLACTINEMIA IN WOMEN OF REPRODUCTIVE AGE WITH DISORDERS OF MENSTRUAL CYCLE

T. Uskoković ,
T. Uskoković

Railway Health Institute, Department of Gynecology and Obstetrics , Belgrade , Serbia

D. Ljušić ,
D. Ljušić

Clinical/Hospital Centre, Gračanica Bosnia and Herzegovina

A. Nikolov
A. Nikolov

Clinical/Hospital Centre, Kragujevac Serbia

Published: 01.12.2010.

Volume 38, Issue 2 (2010)

pp. 89-92;

https://doi.org/10.70949/pramed201002370U

Abstract

Hyperprolactinemia is the most common hypothalamic-pituitary axial disorder which is found in clinical practice. Increased level of prolactin, regardless of the cause, results in disorder of gonadal function and infertility, while normalization of the level of prolactin is associated with establishment of normal gonadal function and fertility. Establishment of the correct diagnosis is a great significance, because it is possible to normalize the level of prolactin and establish normal function of ovaries in more than 90% cases with specific therapy. The objective of the work is to study concentration of prolactin in each phase of menstrual cycle, its impact (influence) on FSH, LH and E2, as well as the influence of hyperprolactinemia on the rhythm of menstrual cycle. The study has encompassed 150 of women in reproductive period, from 18-40 years of age. The control group includes 50 of women, and there are 100 of women with menstrual cycle disorders (oligomenorrhea, polymenorrhea and secondary amenorrhea) which causes hyperprolactinemia. The turnout of hyperprolactinemia in causes the disorders of menstrual cycle (oligomenorrhea, polymenorrhea, amenorrhea) is 83%, on the basis of the results, wich demonstrates a serious problem and justifies a scientific study.

Keywords

References

1.
Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, et al. Guidelines for the Diagnosis and Treatment of Hyperprolactinemia. Journal of Reproductive Medicine. 44(12 Suppl):1075–84.
2.
Limas CJ, Kroupis C, Hairoglou A. Hyperprolactinemia in Patients with Heart Failure: Clinical and Immunogenetic Correlations. European Journal of Clinical Investigation. 32(2):74.
3.
Kostal M, Tosner J. The Influence of Latent Hyperprolactinemia on the Levels of LH, FSH, E2, and T in the Midfollicular Phase of the Cycle. Archives of Gynecology and Obstetrics. 259(2):65–8.
4.
Canonico PL, Judd AM, Koike K, Valdenegro CA, Macleod RME. 116:218.
5.
Giusti M, Fazzoli L, Cavallero D, Valenti S. Circulating Nitric Oxide Change Throughout the Menstrual Cycle in Healthy Women and Women Affected by Pathological Hyperprolactinemia on Dopamine Agonist Therapy. Gynecological Endocrinology. 16(5):407–12.
6.
Fonseca AL, Chimelli L, Santos MJ, Santos AA, Violante AH. Influence of Hyperprolactinemia and Tumoral Size on Postoperative Pituitary Function in Clinically Nonfunctioning Pituitary Macroadenomas. Arquivos de Neuropsiquiatria. 60(30-A):590–602.
7.
Brouwers JRBJ, Addies J, Wiersinga WM. Plasma Prolactin Levels After Acute and Subchronic Oral Administration of Domperidone and Metoclopramide: A Cross-Over Study in Healthy Volunteers. Clinical Endocrinology. 12:435.
8.
Nowakowski G, Widala E, Koshanska Dziurowicz AA. Hyperprolactinemia: I. Etiopatogenesis, Clinical Features. Przegląd Lekarski. 55(7–8):393–6.
9.
K.W. W, R.W. Hyperprolactinemia in Males with Systemic Lupus Erythematosus. Journal of Rheumatology. 25(12):2357–63.
10.
Đurić S. Osnovi Neuroendokrinologije.
11.
Choudhury SD, Goswami A. Hyperprolactinemia and Reproductive Disorders: A Profile from North East India. Journal of the Association of Physicians of India. 43(9):617–8.
12.
Arie MH, Fonseca AM, Arie WM, Carvalho FM, Bagnoli VR, Pinotti JA. Endometrial Prolactin in Hyperprolactinemic Women. Vol. 69.
13.
Tanaka T, Shiu RPC, Beer CT, Friesen HG. A New Sensitive and Specific Bioassay for Lactogenic Hormones: Measurement of Prolactin and Growth Hormone in Human Serum. Journal of Clinical Endocrinology and Metabolism. 51:1058–63.
14.
Laczi F, Szasz A, Vecsernyes M, Julesz J. Neurohypophysial Hormone Secretion in Hyperprolactinemic Women. Neuropeptides. 32(5):435–7.
15.
Blanc MS, Dufau ML. Bioactivity of Asymptomatic Hyperprolactinemic and Normoprolactinemic Women: Basic and Clinical Correlates.
16.
Beckers A, Stevenaert A, Foidart JM, Henen G, Frankenne F. Placental and Pituitary Growth Hormone Secretion During Pregnancy in Women. Journal of Clinical Endocrinology and Metabolism. 71:725–31.
17.
Lean A, Ferland L, Dronin K, Kelly PA, Labrie F. Modulation of Pituitary Thyrotropin Releasing Hormone Receptor Levels by Estrogen and Thyroid Hormones. Endocrinology. 100:1496–504.
18.
Bismar K, Efendic S. Pituitary Function and the Empty Sella Syndrome. Neuroendocrinology. 32:70–7.
19.
Kleinberg DL, Franc AG. Human Prolactin. Journal of Clinical Investigation. 50:1557–68.
20.
Abram F, Linke F, Kajfon A, Tchovelidze C, Chelbi N, Arvis G. Erectile Dysfunction Secondary to Hyperprolactinemia. Progress in Urology. 8(4):537–41.
21.
Arejuwon CA, Ilesanmi AO, Ode EO. Hyperprolactinaemia as a Cause of Male Infertility in Ibadan. West African Journal of Medicine. 18(1):17–9.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by